“The opportunity to target tumor proteins by having an ADC—an antibody hooked up to some harmful payload—truly opens up the chance to test a spread of different targets for an assortment of different indications,” he defined. “It’s continue to early, but excitingly, you can find now quite a few ongoing scientific trials testing vacci